The United States has initiated a trade investigation into Germany’s drug pricing practices, claiming they undervalue innovative medicines. This move aims to determine if Germany’s pricing system unfairly burdens US commerce, leaving American patients to bear higher costs for pharmaceutical research and development.
US Trade Representative Jamieson Greer highlighted concerns over Germany’s planned healthcare reforms, which could further reduce spending on new medicines. The investigation follows a directive from President Trump to address foreign policies that disproportionately impact American patients.
If the investigation finds Germany’s pricing policies discriminatory, the US could impose tariffs or other trade restrictions. This scenario could lead to increased costs for German pharmaceuticals, potentially affecting their availability in the US market.
The outcome of this investigation may reshape the landscape of international pharmaceutical pricing, influencing how countries negotiate drug costs and potentially leading to higher prices for consumers in both markets.
Source: Euronews
